Abstract
Isolated/idiopathic REM sleep behavior disorder (iRBD) and Lewy body dementia (LBD) are synucleinopathies that have partial genetic overlap with Parkinson’s disease (PD). In this study, we examined if the human leukocyte antigen (HLA) locus plays a similar role in iRBD, LBD and PD. The DQA1*01:02∼DQB1*06:02∼DRB1*15:01 haplotype is associated with reduced risk for iRBD (OR=0.72, 95%CI=0.50-0.93, p=2.07*10−3), while the haplotypes DQA1*02:01∼DQB1*03:03∼DRB1*07:01 (OR=1.57; 95%CI=[1.28-1.86]; p=2.45*10−3) and DQA1*05:05∼DQB1*03:01∼DRB1*11:01 (OR=1.39; 95%CI=[1.17-1.60]; p=3.01*10−3) are associated with increased risk for iRBD. This effect was not replicated in LBD. Our results suggest that the HLA locus may have different roles across synucleinopathies.
Summary for Social Media If you and/or a co-author has a Twitter handle that you would like to be tagged, please enter it here. (format: @AUTHORSHANDLE).
@zivganor
What is the current knowledge on the topic?Variants in HLA-DRB1 have been associated with Parkinson’s disease. However, it is unknown whether specific HLA types or variants are associated with isolated REM sleep behavior disorder (iRBD) and dementia with Lewy body dementia (LBD).
What question did this study address?Whether specific HLA types or variants are associated with isolated REM sleep behavior disorder (iRBD) and Lewy body dementia (LBD).
What does this study add to our knowledge?This study suggests an association between three HLA haplotypes and iRBD.
How might this potentially impact on the practice of neurology?Understanding the genetic risk underlying iRBD may help with stratification in clinical studies and trials and provide directions for studying the mechanisms underlying this disorder.
Competing Interest Statement
S.W.S. serves on the Scientific Advisory Council of the Lewy Body Dementia Association and the Multiple System Atrophy Coalition. S.W.S. receives research support from Cerevel Therapeutics.
Funding Statement
This work was financially supported by the Canadian Institutes of Health Research (#476751), the Michael J. Fox Foundation, Parkinson's Society Canada, the Canadian Consortium on Neurodegeneration in Aging (CCNA), and the Canada First Research Excellence Fund (CFREF) awarded to McGill University for the Healthy Brains Healthy Lives (HBHL) program. The Montreal iRBD cohort is supported by the Canadian Institutes of Health Research. J.-F.G. holds a Canada Research Chair on Cognitive Decline in Pathological Aging. Z.G.O. is supported by the Fonds de recherche du QuebecSante (FRQS) Chercheurs boursiers award, and is a William Dawson and Killam Scholar. This research was supported in part by the Intramural Research Program of the U.S. National Institutes of Health (National Institute of NEurological Disorders and Stroke; project number: ZIANS003154).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study participants signed informed consent forms and the study protocol was approved by the Institutional Review Board at McGill University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.